(Q46667078)

24 December 2017

title

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth (English)

1 reference

24 December 2017

14

Michael Karin

1 reference

24 December 2017

Sunil K Noothi

2

0 references

Charles H. Lawrie

object named as

Charles H Lawrie

4

0 references

Robert Z Orlowski

10

object named as

Robert Z Orlowski

1 reference

24 December 2017

author name string

Subrahmanya D Vallabhapurapu

1

1 reference

24 December 2017

Derek A Pullum

3

1 reference

24 December 2017

Rachel Pallapati

5

1 reference

24 December 2017

Veena Potluri

6

1 reference

24 December 2017

Christian Kuntzen

7

1 reference

24 December 2017

Sohaib Khan

8

1 reference

24 December 2017

David R Plas

9

1 reference

24 December 2017

Marta Chesi

11

1 reference

24 December 2017

W Michael Kuehl

12

1 reference

24 December 2017

P Leif Bergsagel

13

1 reference

24 December 2017

Sivakumar Vallabhapurapu

15

1 reference

24 December 2017

language of work or name

English

0 references

publication date

12 October 2015

1 reference

24 December 2017

published in

Nature Communications

1 reference

24 December 2017

volume

6

1 reference

24 December 2017

page(s)

8428

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/ncomms9428

exact match

0 references

cites work

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Genetic events in the pathogenesis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Molecular pathogenesis of multiple myeloma and its premalignant precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Regulation and function of NF-kappaB transcription factors in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

NF-kappaB and cancer: mechanisms and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

NF-kappaB and cancer-identifying targets and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

NF-kappaB in cancer: from innocent bystander to major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Oncogenic activation of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Introduction to NF-kappaB: players, pathways, perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Proteasome inhibitors in multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Why proteasome inhibitors cannot ERADicate multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

The ERK Cascade: Distinct Functions within Various Subcellular Organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

The cancer stem cell hypothesis: a work in progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Stem cell concepts renew cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

BCR-ABL1 expression in multiple myeloma cells: a case of mistaken identity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Reply to MacLeod et al.: Multiple myeloma plasma cells have chameleon characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCOMMS9428

The diverse and complex roles of NF-κB subunits in cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26455434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Early genetic events provide the basis for a clinical classification of multiple myeloma.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26455434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26455434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NCOMMS9428

1 reference

24 December 2017

ADS bibcode

2015NatCo...6.8428V

0 references

1 reference

24 December 2017